Bolivia steps up lithium dealmaking despite growing opposition
Authorities are negotiating contracts with European and Australian firms, according to president of state-owned lithium company YLB.
(via TheNewswire)
Tampa, Florida, United States – The Newswire - January 22, 2025 – CTT Pharmaceuticals Holdings, Inc.(OTC:CTTH) is pleased to announce its intentions to uplist from The OTC Pink Sheets to The OTCQB Venture Market. The company’s stock will continue to trade under the ticker symbol “CTTH”. CTT Pharma will send its application to The OTC this week and anticipates approval towards the end of February. The company recently had a 2 year PCAOB Audit completed, as this is a requirement to uplist to the OTCQB.
The CEO of CTT Pharma Ryan Khouri stated, “Uplisting to the OTCQB Venture Market is a necessary step for CTT Pharma and reflects our commitment to improve transparency, enhance visibility of the company, increase share liquidity, and expand the audience of potential investors. I will notify shareholders of additional news as it becomes available.”
About CTT Pharma
CTT has patented technology in The United States, Europe, Canada and many additional countries to allow many different actives on a dissolvable strip. This includes but is not limited to Nicotine, Vitamins, and Pharmaceuticals. CTT believes that there is a need for our technology in many industries, which includes a smoke-free nicotine strip that can be used as a smoking cessation product. CTT also believes it can help with pain management and anxiety through additional drug applications. CTT Pharma incorporates micelle technology into its drug delivery. These strips would dissolve quickly, deliver low dose options, and offer better bioavailability.
Investor Relations – 813-606-0060
Copyright (c) 2025 TheNewswire - All rights reserved.
